Showing results (5241-5250 of 10,080) with videos related to
Sort By:
Pageof 1,008
Current Pharmaceutical Design|December 12, 2023
PEGylation Strategy for Improving the Pharmacokinetic and Antitumoral Activity of the IL-2 No-alpha MuteinMarianniz Díaz-Hernández, Janoi Chang-Calderón, Miguel Angel Álvarez, et al.Current Pharmaceutical Design|December 6, 2023
Gamma-mangostin Protects S16Y Schwann Cells Against tert-Butyl Hydroperoxide-induced Apoptotic Cell DeathPurin Charoensuksai, Kwanputtha Arunprasert, Audchara Saenkham, et al.Current Pharmaceutical Design|December 1, 2023
Alkaloids as Promising Agents for the Management of Insulin Resistance: A ReviewAyoub Amssayef, Mohamed EddouksCurrent Pharmaceutical Design|November 30, 2023
Design, Molecular Modeling, MD Simulations, Essential Dynamics, ADMET, DFT, Synthesis, Anti-proliferative, and Apoptotic Evaluations of a New Anti-VEGFR-2 Nicotinamide AnalogueIbrahim H Eissa, Eslam B Elkaeed, Hazem Elkady, et al.Current Pharmaceutical Design|December 1, 2023
Treatment of Metastatic Renal Cell Carcinoma with Checkpoint Inhibitors in Clinical Practice in the Volga-Ural Region of the Eurasian ContinentRadmir R Rakhimov, Aleksandr V Sultanbaev, Adel A Izmailov, et al.Current Pharmaceutical Design|November 29, 2023
3D Printable Drug Delivery Systems: Next-generation Healthcare Technology and Regulatory AspectsAnmol Saxena, Rishabha MalviyaCurrent Pharmaceutical Design|November 22, 2023
Nanoparticles Containing Oxaliplatin and the Treatment of Colorectal CancerHanie Mahaki, Mona Mansourian, Zahra Meshkat, et al.Current Pharmaceutical Design|November 22, 2023
Advances in Understanding the Notch Signaling Pathway in the CochleaXiaoying Chen, Huanzhi Wan, Yutong Bai, et al.Current Pharmaceutical Design|November 6, 2023
Current use of Molecular Mechanisms and Signaling Pathways in Targeted Therapy of Prostate CancerVahideh Keyvani, Samaneh Mollazadeh, Nahid Kheradmand, et al.Current Pharmaceutical Design|November 3, 2023
AI-driven Discovery of Celecoxib and Dexamethasone for Exploring their Mode of Action as Human Interleukin (IL-6) Inhibitors to Treat COVID-19-induced Cytokine Storm in HumansIsraa M Shamkh, Mahmoud Elkazzaz, Enas S Radwan, et al.Pageof 1,008